Skip to content
DataLookout
Menu

ATHENANCT07601295

Tiprelestat Versus Placebo When Added to Standard of Care for the Treatment of Pulmonary Arterial Hypertension (PAH)

StatusEnrolling by Invitation
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Enrolling by invitation only Show 4 more changesShow less
    • Lead sponsor: Stanford University to Marlene Rabinovitch, MD
    • Start date changed from estimate of Jul 2026 to Nov 4, 2026
    • Eligibility criteria expanded, about 17 words
    • Site details revised at 3 of 10 sites
  2. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Change in Pulmonary Vascular Resistance (PVR)
Timeframe: Baseline to week 24

Arms and interventions

Tiprelestat (5 mg)Experimental

Participants receive tiprelestat injection daily for 168 days.

Tiprelestat (10 mg)Experimental

Participants receive tiprelestat injection daily for 168 days.

Placebo (1 mL 0.9% saline solution)Placebo comparator

Participants receive placebo injection (matching tiprelestat) daily for 168 days.

Drugs: Tiprelestat (5 mg), Placebo (1 mL 0.9% saline solution), Tiprelestat (10 mg)

Sites

10 sites in 1 country